Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
The DOI matches its Crossref record.
Abstract
Using specific radioimmunoassays, we studied the occurrence of amidated and glycine-extended glucagon-like peptide I (GLP-I) molecules in the human small intestine and pancreas and in the circulation system in response to a breakfast meal. Through gel permeation chromatography of extracts of the human pancreas (n = 5), we found that 71% of the GLP-I immunoreactivity eluted as a large molecule corresponding to the major proglucagon fragment, 24% corresponded to GLP-I 1–36 amide, and 5% to GLP-I 1–37. By gel permeation chromatography of extracts of human small intestine (n = 6), we found that all immunoreactivity eluted in one peak at the common elution position of the two insulin-releasing peptides, GLP-I 7–36 amide and GLP-I 7–37. Of the GLP-I immunoreactivity, 80% corresponded to GLP-I 7–36 amide and 20% to GLP-I 7–37. The mean concentrations of amidated GLP-I and glycine-extended GLP-I in fasting plasma were 7 ± 1 and 6 ± 1 pM, respectively (n = 6). In response to a breakfast meal, the concentration of amidated GLP-I rose significantly amounting to 41 ± 5 pM 90 min after the meal ingestion, whereas the concentration of glycine-extended GLP-I only rose slightly to a maximum of 10 ± 1 pM. Thus, both amidated and glycine-extended GLP-I molecules are produced in the small intestine and in the pancreas in humans. Both amidated and glycine-extended GLP-I are measurable in fasting plasma. The higher meal response of amidated GLP-I compared with glycine-extended GLP-I probably reflects the larger amount of amidated GLP-I produced in the tissues compared with glycine-extended GLP-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Items 101–151 of 151
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“Endogenous GLP-1 is mainly produced as GLP-1(7-36NH2), with a low proportion produced as GLP-1(737) and an even a lower portion as GLP-1(1-37) or GLP-1(136NH2) (29, 57).”
BackgroundBergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Self-citationTolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139
Self-citationInterleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Self-citationGut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Self-citationWinther-Sørensen, M., Galsgaard, K. D., Santos, A., Trammell, S. A. J., Sulek, K., Kuhre, R. E., Pedersen, J., Andersen, D. B., Hassing, A. S., Dall, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101080 · Cited by 135
Self-citationSimonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133
Self-citationExaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia
Toft-Nielsen, M., Madsbad, S., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250051049 · Cited by 132
“ously [23] against standards of synthetic GLP-1(7±36amide) ( = proglucagon 78±107amide) using antiserum code no.”
MethodSelf-citationIs GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
“GLP-1 is cleaved from proglucagon in specific intestinal enterocytes called L cells, and secreted primarily as an amidated 30amino acid peptide GLP-1(7-36)NH2 (1,17).”
BackgroundInfluentialGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“In humans, virtually all GLP-1 is amidated at the C terminus 12,13 , which is important for GLP-1 measurements (Box 1).”
Self-citationIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Lindgren, O., Mari, A., Deacon, C. F., Carr, R. D., Winzell, M. S., Vikman, J., & Ahrén, B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0366 · Cited by 111
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Self-citationHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Effect of GIP and GLP-1 antagonists on insulin release in the rat
Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Postprandial GLP-1, Norepinephrine, and Reactive Hypoglycemia in Dumping Syndrome
Gebhard, B., Holst, J. J., Biegelmayer, C., & Miholic, J. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010635131228 · Cited by 92
“The plasma concentrations of GLP-1 were measured ( 16 ) against standards of synthetic GLP-1 (7‐36 amide) using antiserum code no. 89390, which is specific for the amidated C-terminus of GLP-1 and therefore mainly reacts with GLP-1 of intestinal origin.”
BackgroundMethodSelf-citationDollerup, O. L., Trammell, S. A. J., Hartmann, B., Holst, J. J., Christensen, B., Møller, N., Gillum, M. P., Treebak, J. T., & Jessen, N. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01081 · Cited by 77
Self-citationKCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia
Torekov, S. S., Iepsen, E., Christiansen, M., Linneberg, A., Pedersen, O., Holst, J. J., Kanters, J. K., & Hansen, T. (2014) · Diabetes · doi:10.2337/db13-1454 · Cited by 84
Self-citationKnop, F. K., Konings, E., Timmers, S., Schrauwen, P., Holst, J. J., & Blaak, E. E. (2013) · Diabetic Medicine · doi:10.1111/dme.12231 · Cited by 72
Self-citationØhrstrøm, C. C., Worm, D., Højager, A., Andersen, D., Holst, J. J., Kielgast, U. L., & Hansen, D. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13796 · Cited by 72
Self-citationHe, L., Wong, C. K., Cheung, K. K., Yau, H. C., Fu, A., Zhao, H., Leung, K. M., Kong, A. P., Wong, G. W., Chan, P. K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12063 · Cited by 70
GIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68
Self-citationMatikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63
“The plasma concentrations of GLP-1 were measured (17) against standards of synthetic GLP-1 7-36amide using antiserum code #89390, which is specific for the amidated C-terminus of GLP-1 and therefore does not react with GLP-1containing peptides from the pancreas.”
MethodSelf-citationBergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationHuber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“1 RIA [standardized assay (41)], polyclonal antiserum no. 89390, LOD: 1 pM, intra-assay CV: 6%, speci fi city: 100% for GLP-1 (7 – 36) 89% for GLP-1 (9 – 36); 2 RIA (Merck Millipore), sensitivity: 3 pM, speci fi city: 100% for GLP-1 (7 – 36) and GLP-1 (9 – 36), intra-assay CV: 22 – 36%, inter-assay…”
BackgroundMethodInfluentialSelf-citationYang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Hücking, K., Kostic, Z., Pox, C., Ritzel, R., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01451.x · Cited by 57
Self-citationHøjberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Self-citationAsmar, A., Cramon, P. K., Simonsen, L., Asmar, M., Sorensen, C. M., Madsbad, S., Moro, C., Hartmann, B., Jensen, B. L., Holst, J. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00004 · Cited by 56
Self-citationSamson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Normal physical activity obliterates the deleterious effects of a high-caloric intake
Krogh-Madsen, R., Pedersen, M., Solomon, T. P. J., Knudsen, S. H., Hansen, L. S., Karstoft, K., Lehrskov-Schmidt, L., Pedersen, K. K., Thomsen, C., Holst, J. J., et al. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00155.2013 · Cited by 53
Self-citationDagbasi, A., Lett, A. M., Murphy, K., & Frost, G. (2020) · Proceedings of the Nutrition Society · doi:10.1017/s0029665120006941 · Cited by 44
“In response to the detection of nutrients and other digestive factors, L-cells release GLP-1 and PYY (58,59) .”
Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Watkins, J. D., Koumanov, F., & Gonzalez, J. T. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab078 · Cited by 40
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1121 · Cited by 37
Self-citationvan Raalte, D. H., Diamant, M., Ouwens, D. M., Ijzerman, R. G., Linssen, M. M. L., Guigas, B., Eringa, E. C., & Serné, E. H. (2013) · Diabetologia · doi:10.1007/s00125-013-3016-8 · Cited by 33
“Total glucagon-like peptide (GLP)-1 levels and glucose-dependent insulinotropic peptide (GIP) levels were measured using radioimmunoassays as described previously [22, 23].”
MethodGandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06060-w · Cited by 31
Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
Asmar, A., Cramon, P. K., Asmar, M., Simonsen, L., Sorensen, C. M., Madsbad, S., Hartmann, B., Holst, J. J., Hovind, P., Jensen, B. L., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa643 · Cited by 27
Self-citationBagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes · doi:10.2337/db20-0998 · Cited by 27
Self-citationMersebach, H., Svendsen, O. L., Holst, J. J., Astrup, A., & Feldt‐Rasmussen, U. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01675.x · Cited by 22
Self-citationHOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17549.x · Cited by 21
Self-citationEndurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Self-citationCraig, C. M., Lamendola, C., Holst, J. J., Deacon, C. F., & McLaughlin, T. L. (2015) · AACE Clinical Case Reports · doi:10.4158/ep14218.cr · Cited by 15
Self-citationHigher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion
Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1948 · Cited by 12
Self-citationBrodersen, K., Mose, M., Ramer Mikkelsen, U., Jørgensen, J. O. L., Festersen Nielsen, M., Møller, N., Wegeberg, A., Brock, C., Hartmann, B., Holst, J. J., et al. (2022) · Physiological Reports · doi:10.14814/phy2.15462 · Cited by 4
“Total GLP- 1 was measured as described in (Orskov et al., 1994) using a radioimmunoassay (antibody code no 89390) specific for the C- terminal part of the GLP- 1 molecule and reacting equally with intact GLP- 1 and the primary (N- terminally truncated) metabolite.”
MethodSelf-citation
Metadata
- Authors
- Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1994-04-01
- Volume
- 43
- Issue
- 4
- Pages
- 535-539
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2166073051
- Cited by
- 919
- References
- 0
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.